Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RASolute 304 adjuvant daraxonrasib versus observation in resected PDAC
2025-523495-23-00Phase 3Authorised
- Sponsor
- Revolution Medicines
- Start
- Apr 2026
- Modality
- Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing Adjuvant daraxonrasib with Standard-of-care observation (2 arms). Primary endpoint: Disease-free survival per Investigator. Planned start Apr 2026; status: authorised.
02
Drugs
daraxonrasib
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2025-523495-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-523495-23-00.